Literature DB >> 31283700

Management of Glaucoma in Pregnancy.

Sunu Mathew1, Alon Harris1, Colin M Ridenour1, Barbara M Wirostko2, Kendall M Burgett1, Molly D Scripture1, Brent Siesky1.   

Abstract

Management of glaucoma during pregnancy represents a challenge for the physician. Important disease and patients' health decisions begin even before conception and continue throughout pregnancy and breastfeeding. The data on this topic is limited due to ethical and legal constraints and challenges of conducting large, prospective, and randomized clinical trials on this patient population. Our review suggests that individually, intraocular pressure is lower in a pregnant woman when compared with a nonpregnant woman. Importantly, the medical management of glaucoma during pregnancy poses special challenges due to the possibility of adverse effects of medications on the fetus and newborn. Laser trabeculoplasty and traditional filtration surgery, and minimally invasive glaucoma surgery, represent nondrug management options. Thus, managing glaucoma in pregnancy is a delicate balance between treatment to prevent damage to the optic nerve in the mother and avoidance of interventions potentially harmful to the fetus. This literature review of published individual and population-based studies was performed to explore current knowledge and guidelines in the management of glaucoma in pregnancy.

Entities:  

Year:  2019        PMID: 31283700     DOI: 10.1097/IJG.0000000000001324

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  2 in total

1.  Commentary: Pregnancy hormone to control intraocular pressure?

Authors:  John D Akkara; Anju Kuriakose
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

2.  Glaucoma Progression after Delivery in Patients with Open-Angle Glaucoma Who Discontinued Glaucoma Medication during Pregnancy.

Authors:  Duri Seo; Taekjune Lee; Joo Yeon Kim; Gong Je Seong; Wungrak Choi; Hyong Won Bae; Chan Yun Kim
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.